A Phase I, Non-randomized, Open-label, Fixed-sequence Study to Investigate the Effect of Darolutamide (ODM-201) on the Pharmacokinetics of a Probe Substrate of CYP3A4 and P-gp in Healthy Male Volunteers
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 20 Sep 2017
At a glance
- Drugs Darolutamide (Primary) ; Dabigatran etexilate; Midazolam
- Indications Prostate cancer
- Focus Pharmacokinetics
- Sponsors Bayer
- 14 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 16 Aug 2017 Status changed from not yet recruiting to recruiting.
- 04 Aug 2017 New trial record